AU2004294345B2 - Synthetic HLA binding peptide analogues and uses thereof - Google Patents

Synthetic HLA binding peptide analogues and uses thereof Download PDF

Info

Publication number
AU2004294345B2
AU2004294345B2 AU2004294345A AU2004294345A AU2004294345B2 AU 2004294345 B2 AU2004294345 B2 AU 2004294345B2 AU 2004294345 A AU2004294345 A AU 2004294345A AU 2004294345 A AU2004294345 A AU 2004294345A AU 2004294345 B2 AU2004294345 B2 AU 2004294345B2
Authority
AU
Australia
Prior art keywords
cells
peptide
synthetic peptide
human
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004294345A
Other languages
English (en)
Other versions
AU2004294345A1 (en
Inventor
Javier Pinilla-Ibarz
David Scheinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34652399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004294345(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2004294345A1 publication Critical patent/AU2004294345A1/en
Application granted granted Critical
Publication of AU2004294345B2 publication Critical patent/AU2004294345B2/en
Priority to AU2012202819A priority Critical patent/AU2012202819A1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2004294345A 2003-12-01 2004-11-30 Synthetic HLA binding peptide analogues and uses thereof Expired AU2004294345B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202819A AU2012202819A1 (en) 2003-12-01 2012-05-15 Synthetic HLA binding peptide analogues and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52595503P 2003-12-01 2003-12-01
US60/525,955 2003-12-01
PCT/US2004/040347 WO2005053618A2 (en) 2003-12-01 2004-11-30 Synthetic hla binding peptide analogues and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202819A Division AU2012202819A1 (en) 2003-12-01 2012-05-15 Synthetic HLA binding peptide analogues and uses thereof

Publications (2)

Publication Number Publication Date
AU2004294345A1 AU2004294345A1 (en) 2005-06-16
AU2004294345B2 true AU2004294345B2 (en) 2012-02-23

Family

ID=34652399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004294345A Expired AU2004294345B2 (en) 2003-12-01 2004-11-30 Synthetic HLA binding peptide analogues and uses thereof

Country Status (7)

Country Link
US (3) US7488718B2 (cg-RX-API-DMAC7.html)
EP (2) EP2478913A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007516966A (cg-RX-API-DMAC7.html)
AU (1) AU2004294345B2 (cg-RX-API-DMAC7.html)
CA (1) CA2548135C (cg-RX-API-DMAC7.html)
ES (1) ES2402184T5 (cg-RX-API-DMAC7.html)
WO (1) WO2005053618A2 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127409A1 (en) * 2003-12-01 2006-06-15 Scheinberg David A Bcr-abl vaccines and methods of use thereof
ES2402184T5 (es) * 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) * 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
JP2010504332A (ja) * 2006-09-19 2010-02-12 ヒューマン バイオモレキュラル リサーチ インスティテュート アルツハイマー病の診断方法及び遺伝子マーカー
MX352947B (es) * 2007-02-27 2017-12-14 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
US20100255020A1 (en) * 2007-11-20 2010-10-07 Nec Corporation Method for inducing cytotoxic t-cells, cytotoxic t-cell inducers, and pharmaceutical compositions and vaccines employing them
WO2009072610A1 (ja) * 2007-12-05 2009-06-11 International Institute Of Cancer Immunology, Inc. 癌ワクチン組成物
CA2760041A1 (en) * 2008-05-14 2009-11-19 Simons Haplomics Limited Methods and compositions for the treatment of cancer
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2013018778A1 (ja) 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP3520810A3 (en) * 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US20240408197A1 (en) * 2015-11-20 2024-12-12 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer
HUE059694T2 (hu) 2015-11-20 2022-12-28 Memorial Sloan Kettering Cancer Center Készítmény rák kezelésére
US20190209669A1 (en) 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Wt1ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
US12059463B2 (en) 2017-10-24 2024-08-13 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法
CN114149970B (zh) * 2021-11-09 2024-06-18 因诺伟(北京)生物医疗科技有限公司 一种外周血造血干细胞来源致敏树突状细胞的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2003037060A2 (en) * 2001-10-30 2003-05-08 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
ES2402184T5 (es) * 2003-12-01 2016-10-25 Sloan-Kettering Institute For Cancer Research Análogos de péptidos de unión a HLA sintéticos y sus usos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2003037060A2 (en) * 2001-10-30 2003-05-08 Corixa Corporation Compositions and methods for wt1 specific immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Scardino et al. J. Immunol. 2002, 168(11), 5900-5906 *

Also Published As

Publication number Publication date
ES2402184T5 (es) 2016-10-25
EP1708732B1 (en) 2013-01-02
US7488718B2 (en) 2009-02-10
EP2478913A1 (en) 2012-07-25
JP2007516966A (ja) 2007-06-28
US20100239547A1 (en) 2010-09-23
WO2005053618A2 (en) 2005-06-16
CA2548135C (en) 2014-04-22
ES2402184T3 (es) 2013-04-29
US20050119185A1 (en) 2005-06-02
US20060084609A1 (en) 2006-04-20
WO2005053618A3 (en) 2006-02-23
AU2004294345A1 (en) 2005-06-16
EP1708732A4 (en) 2009-09-02
CA2548135A1 (en) 2005-06-16
EP1708732B2 (en) 2016-05-18
EP1708732A2 (en) 2006-10-11
US7598221B2 (en) 2009-10-06

Similar Documents

Publication Publication Date Title
EP1708732B1 (en) Synthetic hla binding peptide analogues and uses thereof
US12528849B2 (en) WT1 HLA class II-binding peptides and compositions and methods comprising same
CN104684577B (zh) 免疫原性wt-1肽及其使用方法
US9265816B2 (en) Immunogenic WT-1 peptides and methods of use thereof
AU2018241209A1 (en) Immunogenic WT-1 peptides and methods of use thereof
Pinilla-Ibarz et al. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses
JP4051602B2 (ja) 腫瘍抗原
JPWO2001011044A1 (ja) 腫瘍抗原
WO2007047653A2 (en) Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor
WO2007120603A2 (en) Immunogenic bcr-abl peptides and methods of use thereof
AU2012202819A1 (en) Synthetic HLA binding peptide analogues and uses thereof
US20060134129A1 (en) Synthetic HLA binding peptide analogues and uses thereof
US20060127409A1 (en) Bcr-abl vaccines and methods of use thereof
Uenaka et al. Murine leukemia RL 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL)
HK40045843A (en) Immunogenic wt-1 peptides and methods of use thereof
HK40012212A (en) Immunogenic wt-1 peptides and methods of use thereof
HK1233496A1 (en) Immunogenic wt-1 peptides and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired